Trial · NCT00511355
Outcomes47
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 47
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Serum Concentration of Prothrombin Fragments 1 + 2 | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | nmol/L | MEAN |
| PRIMARY | Serum Concentration of D-Dimer | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | mg/L Fibrinogen Equivalent Units (FEU) | MEAN |
| PRIMARY | Activated Protein C (APC) Resistance Ratio (Endogenous Thrombin Potential [ETP]-Based) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Ratio | MEAN |
| PRIMARY | Serum Concentration of Clotting Factor VIIa | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | U/L | MEAN |
| PRIMARY | Serum Concentration of Clotting Factor VIIc | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| SECONDARY | Serum Concentration of Total Testosterone | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | nmol/L | MEAN |
| SECONDARY | Serum Concentration of Free Testosterone | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | pmol/L | MEAN |
| SECONDARY | Serum Concentration of Dehydroepiandrosterone Sulphate (DHEAS) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | umol/L | MEAN |
| PRIMARY | Serum Concentration of Clotting Factor VIII | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | Serum Concentration of Clotting Factor II | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | Serum Concentration of Antithrombin III | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | Serum Concentration of Protein S (Free) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | Serum Concentration of Protein S (Total) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | Serum Concentration of Protein C | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Percent of normal | MEAN |
| PRIMARY | APC Resistance Ratio (Activated Partial Thromboplastin Time [APTT]-Based) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | Ratio | MEAN |
| PRIMARY | Serum Concentration of Sex Hormone Binding Globulin (SHBG) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | nmol/L | MEAN |
| PRIMARY | Serum Concentration of C-Reactive Protein (CRP) | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | mg/L | MEAN |
| PRIMARY | Serum Concentration of Total Cholesterol | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | mmol/L | MEAN |
| PRIMARY | Serum Concentration of High Density Lipoprotein (HDL)-Cholesterol | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | mmol/L | MEAN |
| PRIMARY | Serum Concentration of HDL2-cholesterol | Baseline and Cycle 6 (between Days 15 and 21 of the cycle) | All-participants-treated group; n = number of participants with non-missing baseline value and non-missing change from baseline to Cycle 6 | mmol/L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00511355/outcomes